The Pharmaceutical Research and Manufacturers of America says the US Centers for Medicare and Medicaid Services should not itself initiate experiments with value-based payment approaches. Any demonstrations led by agency's CMMI should focus on "holistic" approaches to health costs.
Efforts by the Centers for Medicare and Medicaid Services to promote value-based contracting for drugs should be limited to working with other agencies to help remove regulatory barriers to such arrangements, the Pharmaceutical Research and Manufacturers of America says in Nov. 20 comments.
The comments respond to a September request for information from CMS seeking suggestions on how its reimbursement laboratory, the Center...
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
